New Report Released on Growing Biotech Sector

LAS VEGAS, April 26, 2018 /PRNewswire/ --

FN Media Group Presents Microcapspeculators.com News Commentary 

Statistics MRC recently released a publication on the growing Biotech market. Factor such as growing demand for agro-based products, reducing cost of DNA sequencing, rising prevalence of chronic disorder are driving the market growth. However, ethical issues associated with clinical trials and risks associated with GM organisms and crops are restraining the market growth. Mentioned in today's commentary includes: Propanc Biopharma Inc. (OTC: PPCB), CASI Pharmaceuticals, Inc. (NASDAQ: CASI), Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), and Insmed Incorporated (NASDAQ: INSM).

Download the full report: https://www.reportbuyer.com/product/5361356

Biotechnology is a set of tools that uses living organisms to make or modify a product, improve plants, trees or animals, or develop microorganisms for specific uses. It is a combination of various technologies, applied together to living cells, including not only biology, but also subjects like mathematics, physics, chemistry and engineering.

By Technology, Nanobiotechnology is expected to dominate the market. Various drug delivery therapies use nanobiotechnology for chronic disorders such as cancer. It involves the advancement of nanoparticle based gold nanoparticles, chemotherapeutic drugs, and quantum dots for molecular diagnosis and nanobiosensors which help in drug delivery and optical imaging. North America accounted for largest market share attributed to the increase in investments in R&D pertaining to new drug discovery.

Some biotechnology stocks to consider if looking to enter the sector include: Propanc Biopharma Inc. (OTCQB: PPCB), CASI Pharmaceuticals, Inc. (NASDAQ: CASI), Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), and Insmed Incorporated (NASDAQ: INSM).

Propanc Biopharma Inc. (OTCQB: PPCB)

Market Cap: 1.32M, current share price: $.062 

Propanc Biopharma Inc. (PPCB), a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, this week announced the completion of a scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency (MHRA), UK, regarding the investigational medicinal product (IMP) manufacturing program for PRP, the Company's lead product candidate. A number of topics were raised and clarified regarding the preparation of a clinical trial application (CTA) for a First-In-Human study in the UK. Key topics included the definition of starting material under Good Manufacturing Practice (GMP) principles, as well as certain tests to be conducted as part of the ongoing quality assurance and control requirements for manufacture of a biological product for human use.

CASI Pharmaceuticals, Inc. (NASDAQ: CASI)

Market Cap: $547.56M, current share price: $7.10 

CASI Pharmaceuticals, Inc. (CASI), a biopharmaceutical company dedicated to bringing high quality, cost-effective pharmaceutical products and innovative oncology therapeutics to patients, announced receipt of a letter from the Center for Drug Evaluation (CDE) (group within the China FDA in charge of technical review) indicating that EVOMELA® (melphalan) for injection has been scheduled for review by the Expert Advisory Anti-Tumor (Oncology) Drugs Committee (the "Advisory Committee"), which is scheduled to take place this week between April 25-26, 2018 (the "Advisory Committee Meeting").

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA)

Market Cap: $638.80M, current share price: $12.34 

Dicerna Pharmaceuticals, Inc. (DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the company has resolved all litigation with Alnylam Pharmaceuticals, Inc. The settlement allows Dicerna to advance all of its key and planned pipeline programs while maintaining a strong balance sheet.

"With today's announcement of a settlement with Alnylam, we are now able to focus the entirety of our resources on the advancement of our key clinical and discovery programs," said Douglas M. Fambrough, Ph.D., president and chief executive officer of Dicerna.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)

Market Cap: $6.30B, current share price: $50.19 

Biogen (BIIB) and Ionis Pharmaceuticals (IONS) announced today they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. This collaboration capitalizes on Biogen's expertise in neuroscience research and drug development and Ionis' leadership in RNA targeted therapies with the goal of developing a broad pipeline of investigational therapies. It builds upon a productive collaboration that produced SPINRAZA, the first and only approved treatment for patients with spinal muscular atrophy.

Today, April 20, 2018, Biogen and Ionis will host company conference calls and webcasts to discuss the new collaboration. Full webcast details can be found below.

Under the terms of the collaboration, Biogen will pay Ionis $1 billion in cash, which will include $625 million to purchase 11,501,153 shares of Ionis common stock at a price of $54.34 per share, at an approximately 25% cash premium, and a $375 million upfront payment. Biogen will have the option to license therapies arising out of this collaboration and will be responsible for their development and commercialization. In addition, Biogen may pay milestone payments, license fees and royalties on net sales.

Insmed Incorporated (NASDAQ: INSM)

Market Cap: $1.96B, current share price: $25.63 

Insmed Incorporated (INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it has submitted its New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) to the U.S. Food and Drug Administration (FDA) for adult patients with Nontuberculous Mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Content Provided By: Microcap Speculators

Email: info@microcapspecualtors.com

Phone: +1-702-720-6310

Website: http://microcapspeculators.com/

For Full Legal Disclaimer Click Here.

DISCLAIMER: Microcapspeculators.com (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM,) and its online brand FinancialNewsMedia.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks included herein by MS. FNM was not compensated by any public company mentioned herein to disseminate this press release on behalf of MS.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact
FN Media Group LLC
e-mail:editor@financialnewsmedia.com
+1-(954)345-0611